Omentin-1 vs Insulin Lispro
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Insulin Lispro (Insulin lispro (B28-Lys, B29-Pro human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Insulin Lispro |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Insulin lispro (B28-Lys, B29-Pro human insulin analog) |
| Molecular Weight | ~35 kDa | 5808.0 Da |
| Half-Life | hours | About 1 hour |
| Amino Acids | 313 | 51 |
| Typical Dose | No approved human dose; research use only | 0.05-0.2 U/kg per meal |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 12000 |
| Research Status | Pre-clinical | Approved |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Insulin Lispro Benefits
- ✓Rapid postprandial glucose control
- ✓Flexible premeal timing
- ✓Predictable onset of action
- ✓Useful in basal-bolus regimens
Omentin-1 Dosing
not established|not established
Insulin Lispro Dosing
Inject SC 0-15 minutes before meals|Adjust dose to carbohydrate intake and premeal glucose|Often paired with a basal insulin
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Lispro Side Effects
- ⚠Hypoglycemia
- ⚠Weight gain
- ⚠Injection-site reactions
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Insulin Lispro
Clinical studies show faster onset and shorter duration than regular insulin, improving post-meal glucose control. It is a standard comparator in diabetes pharmacology and closed-loop insulin-delivery research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.